Introduction
============

Melanoma is one of the most common types of cancer in Denmark and the incidence has increased markedly during the recent decades, and by more than 50% in the present study period (from 1136 cases in 2004 to 1886 cases in 2009).[@b1-clep-4-005] The prognosis is highly dependent on cancer stage at diagnosis, with 5-year survival decreasing from 95.6% in patients with localized melanoma to 15.7% for melanoma with distant metastasis.[@b2-clep-4-005],[@b3-clep-4-005] Staging of melanoma is performed according to the Tumor Node Metastasis (TNM) classification devised by the American Joint Committee on Cancer, in which a given TNM class reflects the severity and spread of the melanoma at the time of diagnosis.[@b4-clep-4-005]

In Denmark, virtually all patients with incident melanoma have been registered in the Danish Cancer Registry (DCR), along with individual and tumor characteristics.[@b5-clep-4-005],[@b6-clep-4-005] Although the DCR is used extensively for descriptive and analytical epidemiological studies, the completeness of the TNM staging has not yet been examined. Knowledge of TNM completeness is important because incomplete stage coding may lead to biased results, especially if the pattern of incompleteness is not random. In this study, we examined the completeness of the TNM staging for melanoma patients in the DCR. To improve our understanding of how the missing data may potentially bias study results, we stratified the analysis of completeness by gender, calendar year, age at diagnosis, and Charlson Comorbidity Index.[@b7-clep-4-005]

Materials and methods
=====================

We performed this nationwide study in Denmark, which has a population of approximately 5.4 million inhabitants.[@b8-clep-4-005] All residents in Denmark are provided with tax-supported medical care. Since 1968, the Danish Civil Registration System has assigned a unique 10-digit personal identification (CPR) number to all Danish residents. This number is used in all Danish registers, allowing unambiguous individual-level data linkage.[@b9-clep-4-005],[@b10-clep-4-005]

Ascertainment of patients with melanoma
---------------------------------------

From the DCR, we identified all patients with a primary diagnosis of melanoma (International Classification of Disease, 10th revision \[ICD-10\] C43) between January 1, 2004 and December 31, 2009. The DCR has recorded information on incident cancers in the Danish population since 1943.[@b5-clep-4-005],[@b6-clep-4-005] Cancer diagnoses have been registered according to the ICD-10 since 1978. Since 2004, stage has been recorded using the TNM classification.[@b6-clep-4-005],[@b11-clep-4-005],[@b12-clep-4-005] From the DCR, we obtained information on date of diagnosis, age, gender, and TNM codes.

Comorbidity data
----------------

Data on the presence of comorbidity were obtained from the Danish National Patient Register (DNPR).[@b13-clep-4-005] The DNPR contains data on all admissions to nonpsychiatric hospitals in Denmark since 1977 and outpatient contacts since 1995 including the CPR number, date of admission/contact and discharge, and diagnosis codes. We described pre-existing comorbidity using the Charlson Comorbidity Index (CCI) based on hospital diagnoses within 10 years preceding the date of melanoma diagnosis.[@b7-clep-4-005],[@b14-clep-4-005] We categorized CCI scores into 0 (low), 1--2 (medium), and 3+ (high). Thygesen et al has recently reported that positive predictive values of CCI diagnoses in the DNPR are high (98.0%, 95% confidence interval \[CI\] 96.9--98.8).[@b14-clep-4-005]

Statistical analysis
--------------------

We computed the completeness and corresponding 95% CI of the TNM staging overall and by each component individually (ie, T, N, and M). Registration of Tx, Nx, and Mx (denoting that information on tumor size, lymph node metastasis, and distant metastasis were not available or could not be assessed) was defined as incomplete. Completeness was calculated as the number of individuals with a complete TNM recording, divided by the total number of patients. We stratified completeness by gender, age (0--39 years, 40--59 years, 60--79 years, and ≥80 years), year of cancer diagnosis, and level of comorbidity. Melanomas with a thickness of 1 mm or thinner (T1) are typically localized and considered non-metastatic, hence patients with these lesions are often not offered sentinel node operation and further examination. Therefore, Nx and Mx are often used for T1 melanomas because N0 and M0 status has not been confirmed. Therefore, as a sensitivity analysis, we conducted a subanalysis in which we included melanomas assigned T1, Nx, Mx in our definition of complete staging. In addition, we performed a sensitivity analysis restricted to patients with histologically verified melanoma. Finally, we designed an algorithm that allowed us to categorize stage as localized, regional, distant, or unknown according to the codes for "T" (tumor), "N" (lymph node), and "M" (metastasis), as shown in [Appendix 1](#t1-clep-4-005){ref-type="table"}. For each of the three definite stages, missing data were allowed if the available information provided sufficient and clinically meaningful information to categorize cases. The unknown tumor category included primarily locally advanced tumors (T3 or T4) with unknown N and/or M stage.

Analyses were performed using SAS (version 9.2; SAS Institute Inc, Cary, NC).

Results
=======

We identified 8762 patients registered with primary melanoma in the DCR from 2004 to 2009. Of these, 4844 (55.3%) were women, and the median age at diagnosis was 56 years (interquartile range 41--69 years) for women and 62 years (interquartile range 50--72 years) for men.

The overall completeness of the TNM staging was 78.4% (95% CI 77.5--79.3, [Table 1](#t1-clep-4-005){ref-type="table"}) and the proportion increased only marginally by redefining T1, Nx, Mx as complete (80.0% \[95% CI 79.2--80.8\]). Nearly all melanoma cases were histologically verified (96.8%), and thus restricting the analyses to these did not change the overall completeness (78.5% versus 78.4%). During the study period, TNM completeness was slightly higher for women than for men, 80.1% (95% CI 79.0--81.2) versus 76.3% (95% CI 74.9--77.6), but otherwise did not reveal any overall trends. In contrast, completeness declined with increasing age, from 83.5% (95% CI 81.7-- 85.3) among patients aged 0--39 years to 68.7% (95% CI 65.7--71.6) in those aged 80 years or more, as well as with level of comorbidity, from 80.3% (95% CI 79.4--81.3) in patients with low comorbidity (CCI score 0) to 67.4% (95% CI 63.1--71.4) among those with high level of comorbidity (CCI score 3+). When examining the completeness of T, N, and M separately, we observed a slightly lower completeness of N (84.7%) compared with T (88.5%) and M (88.7%). Similar to the overall TNM registration, the completeness of the individual stage components decreased with increasing age and level of comorbidity.

Using the algorithm ([Appendix 1](#t1-clep-4-005){ref-type="table"}), allowing Tx, Nx, and Mx codes to be included in the definite stage categories, the proportion of tumors with unknown stage decreased from 21.6% to 12.7% ([Table 2](#t2-clep-4-005){ref-type="table"}). Compared with patients with known cancer stage, patients with unknown cancer stage were more frequently males (49.8% versus 44.0%) and of higher age (80 years or more, 18.2% versus 10.0%). Furthermore, medium or high CCI scores were assigned to 30.0% of those with unknown cancer stage compared with 22.3% of those with known cancer stage. The staging completeness among patients aged 0--39 years was 90.5%, and 79.0% among those aged 80 years or more. Among patients with low comorbidity, the completeness was 88.4% versus 82.1% among those with high level of comorbidity.

Discussion
==========

In this nationwide study, we found an overall completeness of TNM staging for melanoma of 78%. The completeness varied by age and level of comorbidity and was lowest among the elderly and those with high levels of comorbidity. When we applied a stage algorithm that allowed some missing values of T, N, and M, the overall proportion of patients with unknown stage decreased to 12.7%; however, elderly and/or high comorbidity patients still exhibited the highest proportions of unknown stage. To our knowledge, no studies have yet evaluated the completeness of the TNM staging in the DCR. Compatible with our findings, studies of other cancer registries have shown that the proportion of patients with unknown cancer stage is higher for elderly patients with breast, prostate, and colorectal cancer.[@b15-clep-4-005],[@b16-clep-4-005]

Based on our results and those of other studies, it is imperative to consider the variation in TNM staging according to age and level of comorbidity in studies based on cancer registry data. Restricting analyses to patients with complete data on staging is likely to introduce selection bias and lead to incorrect conclusions. In some studies, cases of unknown stage have been categorized as a separate group, or they have been combined with the definite stage category (eg, distant) that they resemble the most in terms of survival or other characteristics. However, studies have revealed that patients with unknown cancer stage do not typically resemble patients with metastases.[@b2-clep-4-005],[@b17-clep-4-005] In a study of survival of melanoma patients in the United States during the period 1992 to 2005, Pollack et al reported that patients with unknown cancer stage had a 5-year survival of 80.3% compared with 95.6% for patients with localized melanoma and 63.7% for those with regional disease.[@b2-clep-4-005] Alternatively, patients with missing data on stage can be replaced by plausible values predicted from individuals with available data using statistical methods such as multiple imputation.[@b16-clep-4-005],[@b18-clep-4-005]

The main strengths of our study include the nationwide approach using data from a cancer registry with virtually complete registration of melanoma and other cancer diagnoses, its large size, and the availability of data from civil and patient registers that enabled us to examine TNM completeness according to level of comorbidity. However, we only examined the completeness of the TNM staging, and our study approach did not allow for any evaluation of the accuracy of the TNM coding.

Conclusion
==========

In conclusion, we found that the overall registration of TNM staging for melanoma in the DCR was fairly high. However, older age and a higher level of comorbidity were associated with incomplete TNM registration. Thus, data on TNM stage should be used with caution in epidemiological and other research, with consideration of missing data according to age and level of comorbidity.
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###### 

Algorithm for staging of melanoma according to the TNM classification

  Stage       TNM classification
  ----------- ----------------------
  Localized   T1 Nx M0, x
              T1--2 N0 Mx
              T1--4, x N0 M0
  Regional    T1--4, x N1--3 M0
  Distant     T1--4, x N0--3, x M1
  Unknown     T1--4, x N1--3 Mx
              T2--4, x Nx M0, x
              T3--4, x N0 Mx

**Note:** 24 patients (0.3%) coded with T0, Ta, or Tis were added to the unknown stage category, since these codes are not clinically meaningful for melanoma.

**Abbreviation:** TNM, tumor, node, metastasis.

###### 

Completeness of TNM staging among melanoma patients in the Danish Cancer Registry

                      Total number of patients   TNM completeness   T completeness      N completeness   M completeness                                        
  ------------------- -------------------------- ------------------ ------------------- ---------------- ------------------- ------ ------------------- ------ -------------------
  Total               8762                       6869               78.4 (77.5--79.3)   7754             88.5 (87.8--89.2)   7424   84.7 (84.0--85.5)   7770   88.7 (88.0--89.3)
  Gender                                                                                                                                                       
   Female             4844                       3880               80.1 (79.0--81.2)   4345             89.7 (88.8--90.5)   4153   85.7 (84.7--86.7)   4326   89.3 (88.4--90.2)
   Male               3918                       2989               76.3 (74.9--77.6)   3409             87.0 (85.9--88.0)   3271   83.5 (82.3--84.6)   3444   87.9 (86.9--88.9)
  Age group (years)                                                                                                                                            
   0--39              1615                       1349               83.5 (81.7--85.3)   1497             92.7 (91.4--93.9)   1417   87.7 (86.1--89.3)   1474   91.3 (89.8--92.6)
   40--59             2845                       2299               80.8 (79.3--82.2)   2546             89.5 (88.3--90.6)   2459   86.4 (85.1--87.7)   2569   90.3 (89.2--91.4)
   60--79             3334                       2556               76.7 (75.2--78.1)   2899             87.0 (85.8--88.1)   2805   84.1 (82.9--85.3)   2935   88.0 (86.9--89.1)
   ≥80                968                        665                68.7 (65.7--71.6)   812              83.9 (81.5--86.1)   743    76.8 (74.0--79.3)   792    81.8 (79.3--84.2)
  Year of diagnosis                                                                                                                                            
   2004               1152                       867                75.3 (72.7--77.7)   958              83.2 (80.9--85.2)   978    84.9 (82.7--86.9)   1005   87.2 (85.2--89.1)
   2005               1400                       1115               79.6 (77.5--81.7)   1228             87.7 (85.9--89.4)   1221   87.2 (85.4--88.9)   1265   90.4 (88.7--91.8)
   2006               1430                       1152               80.6 (78.5--82.6)   1311             91.7 (90.2--93.0)   1244   87.0 (85.2--88.7)   1301   91.0 (89.4--92.4)
   2007               1481                       1156               78.1 (75.9--80.1)   1314             88.7 (87.0--90.3)   1220   82.4 (80.4--84.3)   1302   87.9 (86.2--89.5)
   2008               1478                       1125               76.1 (73.9--78.2)   1315             89.0 (87.3--90.5)   1227   83.0 (81.0--84.9)   1273   86.1 (84.3--87.8)
   2009               1821                       1454               79.8 (78.0--81.6)   1628             89.4 (87.9--90.8)   1534   84.2 (82.5--85.9)   1624   89.2 (87.7--90.6)
  CCI score                                                                                                                                                    
   Low (0)            6722                       5401               80.3 (79.4--81.3)   6031             89.7 (89.0--90.4)   5801   86.3 (85.5--87.1)   6029   89.7 (89.0--90.4)
   Medium (1--2)      1559                       1144               73.4 (71.1--75.5)   1328             85.2 (83.4--86.9)   1260   80.8 (78.8--82.7)   1334   85.6 (83.8--87.3)
   High (3+)          481                        324                67.4 (63.1--71.4)   395              82.1 (78.5--85.4)   363    75.5 (71.5--79.2)   407    84.6 (81.2--87.6)
  Subanalysis         8762                       7011               80.0 (79.2--80.8)                                                                          

**Abbreviations:** CI, confidence interval; CCI, Charlson Comorbidity Index (excluding melanoma); TNM, tumor, node, metastasis.

###### 

Staging of melanoma patients in the Danish Cancer Registry by year of diagnosis, gender, age group, and CCI score

                      Cancer stage                                                        
  ------------------- -------------- ------ ----- ----- ----- ------ ------ ------ ------ ------
  Total               6621           75.6   660   7.5   367   4.2    1114   12.7   7648   87.3
  Gender                                                                                  
   Female             3825           79.0   305   6.3   155   3.2    559    11.5   4285   88.5
   Male               2796           71.4   355   9.1   212   5.4    555    14.2   3363   85.8
  Age group (years)                                                                       
   0--39              1327           82.2   102   6.3   33    2.0    153    9.5    1462   90.5
   40--59             2179           76.6   240   8.4   121   4.3    305    10.7   2540   89.3
   60--79             2434           73.0   278   8.3   169   5.1    453    13.6   2881   86.4
   ≥80                681            70.4   40    4.1   44    4.5    203    21.0   765    79.0
  Year of diagnosis                                                                       
   2004               808            70.1   108   9.4   53    4.6    183    15.9   969    84.1
   2005               1066           76.1   112   8.0   63    4.5    159    11.4   1241   88.6
   2006               1126           78.7   106   7.4   58    4.1    140    9.8    1290   90.2
   2007               1106           74.7   111   7.5   58    3.9    206    13.9   1275   86.1
   2008               1118           75.6   107   7.2   66    4.5    187    12.7   1291   87.3
   2009               1397           76.7   116   6.4   69    3.8    239    13.1   1582   86.9
  CCI score                                                                               
   Low (0)            5204           77.4   522   7.8   216   3.2    780    11.6   5942   88.4
   Medium (1--2)      1114           71.5   111   7.1   86    5.5    248    15.9   1311   84.1
   High (3+)          303            63.0   27    5.6   65    13.5   86     17.9   395    82.1

**Abbreviation:** CCI, Charlson Comorbidity Index (excluding melanoma).
